It was discovered that its level in a prostate cancer was raised, showing a pro-oncogenic character; however, in other tumor types (skin tumor, fibrosarcoma, and glioblastoma), EGR1 exhibits features of a tumor suppressor by activating p53 and PTEN to halt the transcription of other genes in the mTOR pathway (Zheng et al., 2009). This evidence concerns the gene MTOR and prostate carcinoma.